Evidence map›Paper›PMID 41703992›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

TGM2 Aggravates Acute Pancreatitis by Impairing Macrophage Efferocytosis Through Inhibition of the STAT6-GAS6 Axis.

Xuxu Liu, Zhiwei Du, Liyi Wang, Zhihong Xie, Ziang Meng, Yi Zheng, Heming Wang, Yuanhang He, Dongbo Xue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xuxu LiuKey Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, China.ORCID https://orcid.org/0000-0001-5408-4746
Zhiwei DuKey Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Liyi WangKey Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Zhihong XieKey Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Ziang MengKey Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Yi ZhengKey Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Heming WangKey Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Yuanhang HeKey Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Dongbo XueKey Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, China.ORCID https://orcid.org/0000-0001-9012-4805

Funding

Key Research and Development Program of Heilongjiang Province 2022ZX06C06National Natural Science Foundation of China 82370650
6 · The paper itself

Abstract

backgroundAcute pancreatitis (AP) is characterized by dysregulated inflammation, with macrophage dysfunction (impaired efferocytosis, pro/anti-inflammatory phenotype imbalance) exacerbating the disease. Current therapies are mostly supportive, highlighting the critical need for targeted interventions.

methodsTransglutaminase 2 (TGM2) was identified via public transcriptomic analysis. Its function was validated in caerulein-induced AP mice and in vitro cell models; mechanisms were explored via Co-IP, ChIP, and dual-luciferase assays. A lactoferrin-modified, ROS-responsive LF-LNP system was developed for TGM2 siRNA delivery.

resultsTGM2 was upregulated in AP; its inhibition alleviated pancreatic injury and inflammation. Mechanistically, TGM2 bound STAT6 to suppress its phosphorylation/nuclear translocation, downregulating efferocytosis-related GAS6 and impairing macrophage efferocytosis. LF-LNP@si-TGM2 targeted pancreatic macrophages, silenced TGM2, restored the STAT6-GAS6 axis, enhanced efferocytosis, and reduced inflammation.

conclusionThis study identifies TGM2 as a key regulator of AP macrophage efferocytosis via the novel TGM2-STAT6-GAS6 axis. LF-LNP@si-TGM2 is a promising targeted strategy for AP, potentially shifting treatment from supportive to precision therapy.

Indexed as

Intercellular Signaling Peptides and ProteinsMacrophagesPancreatitisProtein Glutamine gamma Glutamyltransferase 2STAT6 Transcription FactorAnimalsDisease Models, AnimalEfferocytosisGrowth Arrest-Specific Protein 6HumansMaleMiceMice, Inbred C57BLGrowth Arrest-Specific Protein 6Intercellular Signaling Peptides and ProteinsProtein Glutamine gamma Glutamyltransferase 2Stat6 protein, mouseSTAT6 Transcription FactorTGM2 protein, humanacute pancreatitisefferocytosisGAS6lipid nanoparticlesTGM2

Identifiers

PMID41703992
PMCPMC13116110

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.